Gas Shortages Pose Threat to Pharmaceutical Supply Chain Stability

Propane Shortage Hits Indian Pharmaceutical Industry

A severe scarcity of propane has forced multiple pharmaceutical units across Gujarat, Maharashtra, Telangana, and Andhra Pradesh to scale down or suspend operations. This disruption is affecting the output of essential treatments, including fever reducers, nutritional supplements, and hormone-based therapies.

Industry Insights

The Indian pharmaceutical industry relies heavily on propane as a primary fuel source to power boilers and sustain energy-intensive operations involved in API (Active Pharmaceutical Ingredient) manufacturing. Industry insiders indicate that boiler-dependent processes have been hit hard, raising concerns of declining output and possible medicine shortages in the coming weeks as firms rely on existing stock while renegotiating fuel supplies.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Impact on Production

India, a global hub for bulk drug manufacturing, houses large API facilities responsible for producing a wide range of widely used medicines. Sector experts warn that nearly 200 units could face shutdown within the next seven to 10 days. The energy crisis risks delaying production cycles, driving up costs and weakening India's standing in global pharmaceutical supply chains.

Government Response

Manufacturers have urged the government for relief measures, including exemptions similar to those during the pandemic, allowing them to continue manufacturing under the essential commodities list. Experts caution that continued disruption could have widespread implications for both domestic healthcare and international drug availability.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Key Statistics

• 200 units at risk of shutdown
• Seven to 10 days timeframe for potential shutdowns
• API (Active Pharmaceutical Ingredient) manufacturing heavily reliant on propane
• India a global hub for bulk drug manufacturing